A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Clinical trial NCT03650491 · COMPLETED

Trial details

NCT number: NCT03650491
Sponsor: Fortis Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma Multiple Myeloma in Relapse Multiple Myeloma With Failed Remission

Start date: 2019-04-03
Primary completion: 2022-01-31
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.